Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
Go back to Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 25.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.72 | 52 Week High | $117.12 | |||
| Open | $25.72 | 52 Week Low | $46.52 | |||
| Day High | $25.72 | P/E | N/A | |||
| Day Low | $25.72 | EPS | $-1.97 | |||
| Volume | 5,965 | |||||
